UK markets closed
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • FTSE 250

    20,910.37
    -287.75 (-1.36%)
     
  • AIM

    1,183.25
    -8.61 (-0.72%)
     
  • GBP/EUR

    1.1532
    +0.0034 (+0.30%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • BTC-GBP

    34,069.26
    -109.42 (-0.32%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • DOW

    30,932.37
    -469.64 (-1.50%)
     
  • CRUDE OIL

    61.66
    -1.87 (-2.94%)
     
  • GOLD FUTURES

    1,733.00
    -42.40 (-2.39%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     
  • DAX

    13,786.29
    -93.04 (-0.67%)
     
  • CAC 40

    5,703.22
    -80.67 (-1.39%)
     

Infinity Pharmaceuticals to Participate in Three Investor Conferences This Month

·2-min read

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7-8 and 11-14, 2021.

Details for all three investor conferences are as follows:

39th Annual J.P. Morgan Healthcare Conference - Corporate Presentation

Date:

January 14, 2021

Time:

2:00 p.m. ET

Webcast:

Audio-only Link to Webcast Here

2021 LifeSci Advisors - Corporate Access Event

Date:

January 7-13, 2021

Time:

Management available for 1x1 meetings

H.C. Wainwright BioConnect 2021 Conference - Corporate Presentation

Date:

January 11-14, 2021

The session time is on-demand, beginning Monday January 11 starting 6:00 a.m. ET.

To register and view the presentation, please click here.

A replay for all conferences will be available on the Events and Presentations section investor section of the Infinity Pharmaceuticals website https://investors.infi.com/events-and-presentations/upcoming-events following the conference.

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.

Tecentriq® is a registered trademark of Genentech, Inc.

Abraxane® is a registered trademark of Abraxis BioScience, LLC.

Avastin® is a registered trademark of Genentech, Inc.

Doxil® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005217/en/

Contacts

Ashley Robinson
LifeSci Advisors, LLC
617-775-5956